282 related articles for article (PubMed ID: 25515960)
41. [Research advances in the role of JAK2 mutations in acute leukemia].
Zhang HY; Zhai XW
Zhongguo Dang Dai Er Ke Za Zhi; 2015 Jun; 17(6):644-9. PubMed ID: 26108332
[TBL] [Abstract][Full Text] [Related]
42. Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome.
Bercovich D; Ganmore I; Scott LM; Wainreb G; Birger Y; Elimelech A; Shochat C; Cazzaniga G; Biondi A; Basso G; Cario G; Schrappe M; Stanulla M; Strehl S; Haas OA; Mann G; Binder V; Borkhardt A; Kempski H; Trka J; Bielorei B; Avigad S; Stark B; Smith O; Dastugue N; Bourquin JP; Tal NB; Green AR; Izraeli S
Lancet; 2008 Oct; 372(9648):1484-92. PubMed ID: 18805579
[TBL] [Abstract][Full Text] [Related]
43. JAK2 rearrangements, including the novel SEC31A-JAK2 fusion, are recurrent in classical Hodgkin lymphoma.
Van Roosbroeck K; Cox L; Tousseyn T; Lahortiga I; Gielen O; Cauwelier B; De Paepe P; Verhoef G; Marynen P; Vandenberghe P; De Wolf-Peeters C; Cools J; Wlodarska I
Blood; 2011 Apr; 117(15):4056-64. PubMed ID: 21325169
[TBL] [Abstract][Full Text] [Related]
44. Ebf1 or Pax5 haploinsufficiency synergizes with STAT5 activation to initiate acute lymphoblastic leukemia.
Heltemes-Harris LM; Willette MJ; Ramsey LB; Qiu YH; Neeley ES; Zhang N; Thomas DA; Koeuth T; Baechler EC; Kornblau SM; Farrar MA
J Exp Med; 2011 Jun; 208(6):1135-49. PubMed ID: 21606506
[TBL] [Abstract][Full Text] [Related]
45. Clinicopathologic characteristics, genetic features, and treatment options for acute lymphoblastic leukemia with JAK2 rearrangement-A 10-case study and literature review.
Zhang L; Shah B; Zhang Y; Tashkandi H; Xiao W; Fernandez-Pol S; Vergara-Lluri M; Hussaini M; Song J; Lancet J; Moscinski L; Yun S; Lu CM; Medeiros LJ; Tang G
Hum Pathol; 2023 Jun; 136():1-15. PubMed ID: 36958463
[TBL] [Abstract][Full Text] [Related]
46. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia.
Lacronique V; Boureux A; Valle VD; Poirel H; Quang CT; Mauchauffé M; Berthou C; Lessard M; Berger R; Ghysdael J; Bernard OA
Science; 1997 Nov; 278(5341):1309-12. PubMed ID: 9360930
[TBL] [Abstract][Full Text] [Related]
47. Evaluation of PAX5 gene in the early stages of leukemic B cells in the childhood B cell acute lymphoblastic leukemia.
Firtina S; Sayitoglu M; Hatirnaz O; Erbilgin Y; Oztunc C; Cinar S; Yildiz I; Celkan T; Anak S; Unuvar A; Devecioglu O; Timur C; Aydogan G; Akcay A; Atay D; Turkkan E; Karaman S; Orhaner B; Sarper N; Deniz G; Ozbek U
Leuk Res; 2012 Jan; 36(1):87-92. PubMed ID: 21813177
[TBL] [Abstract][Full Text] [Related]
48. The Current Genomic and Molecular Landscape of Philadelphia-like Acute Lymphoblastic Leukemia.
Shiraz P; Payne KJ; Muffly L
Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32235787
[TBL] [Abstract][Full Text] [Related]
49. Loss of Pax5 Exploits Sca1-BCR-ABL
Martín-Lorenzo A; Auer F; Chan LN; García-Ramírez I; González-Herrero I; Rodríguez-Hernández G; Bartenhagen C; Dugas M; Gombert M; Ginzel S; Blanco O; Orfao A; Alonso-López D; Rivas JL; García-Cenador MB; García-Criado FJ; Müschen M; Sánchez-García I; Borkhardt A; Vicente-Dueñas C; Hauer J
Cancer Res; 2018 May; 78(10):2669-2679. PubMed ID: 29490943
[TBL] [Abstract][Full Text] [Related]
50. Interleukin-7 signaling in human B cell precursor acute lymphoblastic leukemia cells and murine BAF3 cells involves activation of STAT1 and STAT5 mediated via the interleukin-7 receptor alpha chain.
van der Plas DC; Smiers F; Pouwels K; Hoefsloot LH; Löwenberg B; Touw IP
Leukemia; 1996 Aug; 10(8):1317-25. PubMed ID: 8709637
[TBL] [Abstract][Full Text] [Related]
51. The correlation between Pax5 deletion and patients survival in Iranian children with precursor B-cell acute lymphocytic leukemia.
Moafi A; Zojaji A; Salehi R; Najafi Dorcheh S; Rahgozar S
Cell Mol Biol (Noisy-le-grand); 2017 Aug; 63(8):19-22. PubMed ID: 28886309
[TBL] [Abstract][Full Text] [Related]
52. Identification of a novel GOLGA4-JAK2 fusion gene in B-cell acute lymphoblastic leukaemia.
Downes CEJ; Rehn J; Heatley SL; Yeung D; McClure BJ; White DL
Br J Haematol; 2022 Feb; 196(3):700-705. PubMed ID: 34697799
[TBL] [Abstract][Full Text] [Related]
53. The combination of ruxolitinib and Bcl-2/Mcl-1 inhibitors has a synergistic effect on leukemic cells carrying a SPAG9::JAK2 fusion.
Mayumi A; Tomii T; Kanayama T; Mikami T; Tanaka K; Ueno H; Yoshida H; Kato I; Kawamura M; Nakahata T; Takita J; Hosoi H; Imamura T
Cancer Gene Ther; 2022 Dec; 29(12):1930-1938. PubMed ID: 35879405
[TBL] [Abstract][Full Text] [Related]
54. Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group.
Hertzberg L; Vendramini E; Ganmore I; Cazzaniga G; Schmitz M; Chalker J; Shiloh R; Iacobucci I; Shochat C; Zeligson S; Cario G; Stanulla M; Strehl S; Russell LJ; Harrison CJ; Bornhauser B; Yoda A; Rechavi G; Bercovich D; Borkhardt A; Kempski H; te Kronnie G; Bourquin JP; Domany E; Izraeli S
Blood; 2010 Feb; 115(5):1006-17. PubMed ID: 19965641
[TBL] [Abstract][Full Text] [Related]
55. Identification of RNPC3 as a novel JAK2 fusion partner gene in B-acute lymphoblastic leukemia refractory to combination therapy including ruxolitinib.
Chen X; Wang F; Zhang Y; Ma X; Liu M; Cao P; Zhou L; Wang L; Zhang X; Wang T; Liu H
Mol Genet Genomic Med; 2020 Mar; 8(3):e1110. PubMed ID: 31885183
[TBL] [Abstract][Full Text] [Related]
56. [Mutation and expression of PAX5 gene in adult acute lymphoblastic leukemia].
Lin ZK; Zhang R; Ge Z; Xu JY; Liu J; Guo X; Li M; Wu YJ; Qiao C; Qiu HR; Zhang JF; Li JY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Oct; 22(5):1206-11. PubMed ID: 25338558
[TBL] [Abstract][Full Text] [Related]
57. Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl.
Carlesso N; Frank DA; Griffin JD
J Exp Med; 1996 Mar; 183(3):811-20. PubMed ID: 8642285
[TBL] [Abstract][Full Text] [Related]
58. Differential expression of MUC4, GPR110 and IL2RA defines two groups of CRLF2-rearranged acute lymphoblastic leukemia patients with distinct secondary lesions.
Sadras T; Heatley SL; Kok CH; Dang P; Galbraith KM; McClure BJ; Muskovic W; Venn NC; Moore S; Osborn M; Revesz T; Moore AS; Hughes TP; Yeung D; Sutton R; White DL
Cancer Lett; 2017 Nov; 408():92-101. PubMed ID: 28866095
[TBL] [Abstract][Full Text] [Related]
59. Mutations in TP53 and JAK2 are independent prognostic biomarkers in B-cell precursor acute lymphoblastic leukaemia.
Forero-Castro M; Robledo C; Benito R; Bodega-Mayor I; Rapado I; Hernández-Sánchez M; Abáigar M; Maria Hernández-Sánchez J; Quijada-Álamo M; María Sánchez-Pina J; Sala-Valdés M; Araujo-Silva F; Kohlmann A; Luis Fuster J; Arefi M; de Las Heras N; Riesco S; Rodríguez JN; Hermosín L; Ribera J; Camos Guijosa M; Ramírez M; de Heredia Rubio CD; Barragán E; Martínez J; Ribera JM; Fernández-Ruiz E; Hernández-Rivas JM
Br J Cancer; 2017 Jul; 117(2):256-265. PubMed ID: 28557976
[TBL] [Abstract][Full Text] [Related]
60. Modulation of Janus kinase 2 by cisplatin in cancer cells.
Song H; Sondak VK; Barber DL; Reid TJ; Lin J
Int J Oncol; 2004 Apr; 24(4):1017-26. PubMed ID: 15010843
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
